{"id":"W4220992683","doi":"10.1158/1538-7445.sabcs21-p5-13-03","title":"Abstract P5-13-03: Alpelisib + endocrine therapy (ET) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), <i>PIK3CA</i>-mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i): Biomarker analyses from the Phase II BYLieve study","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Fulvestrant; Internal medicine; Cohort; Letrozole; Breast cancer; Oncology; Hazard ratio; Cancer; Clinical endpoint; Progression-free survival; Estrogen receptor; Confidence interval; Aromatase; Clinical trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001307712,0.0003150309,0.0006528178,0.0001821848,0.0001342395,0.0006749144,0.0002880575,0.0003258332,0.002101625],"category_scores_gemma":[0.0008427274,0.000103815,0.00071749,0.0002562961,0.0001985742,0.0003654012,0.0002958748,0.0009770362,0.0003446683],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005320797,"about_ca_system_score_gemma":0.0007046433,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006914051,"about_ca_topic_score_gemma":0.001711612,"domain_scores_codex":[0.9996693,0.0001768923,0.00002074408,0.00005159748,0.00004131827,0.00004012828],"domain_scores_gemma":[0.9994597,0.0001250954,0.0001546491,0.00003795659,0.00004689003,0.0001757158],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4224013,0.00765408,0.3029607,0.001000808,0.002487993,0.0003019661,0.000252405,0.00225519,0.03049311,0.0005142201,0.01094791,0.2187302],"study_design_scores_gemma":[0.1164772,0.2660149,0.5742484,0.0002605339,0.00273733,0.001325916,0.0002732065,0.005775191,0.01186816,0.0006255312,0.02032542,0.0000681678],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9955172,0.001393263,0.0001766348,0.0002626705,0.00002485365,0.0001336964,0.001242146,0.00002315881,0.001226478],"genre_scores_gemma":[0.9941283,0.0006367923,0.0004195647,0.0003395793,0.00006161449,0.000146966,0.00340486,0.000009611425,0.0008526974],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002101625,"threshold_uncertainty_score":0.007030666,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05369898673042435,"score_gpt":0.4015396400403317,"score_spread":0.3478406533099073,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}